×
More Charts Below
Calithera Biosciences Total Liabilities and Share Holders Equity 2013-2022 | CALA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Recent Trends
Calithera Biosciences total liabilities and share holders equity from 2013 to 2022. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$95B
Zoetis (ZTS)
$66.3B
Takeda Pharmaceutical (TAK)
$46.8B
Daiichi Sankyo, - (DSNKY)
$41.7B
Summit Therapeutics (SMMT)
$18.2B
Sandoz Group AG (SDZNY)
$17.7B
Merck (MKKGY)
$17.2B
Astellas Pharma (ALPMY)
$16.9B
Shionogi (SGIOY)
$14.1B
United Therapeutics (UTHR)
$12.8B
Neurocrine Biosciences (NBIX)
$10B
IPSEN (IPSEY)
$8.6B
Orion OYJ (ORINY)
$8B
Madrigal Pharmaceuticals (MDGL)
$6.7B
Stevanato Group S.p.A (STVN)
$6.6B
Corcept Therapeutics (CORT)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$5.8B
Ono Pharmaceutical (OPHLF)
$5.5B
Grifols, S.A (GRFS)
$4.9B
Ionis Pharmaceuticals (IONS)
$4.5B
Soleno Therapeutics (SLNO)
$3.2B
Crinetics Pharmaceuticals (CRNX)
$2.8B
Catalyst Pharmaceuticals (CPRX)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.3B
Recursion Pharmaceuticals (RXRX)
$2.2B
Hypermarcas (HYPMY)
$2.1B
NewAmsterdam Pharma (NAMS)
$1.8B
Centessa Pharmaceuticals (CNTA)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.5B
Guardian Pharmacy Services (GRDN)
$1.5B